.Attributes Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin resulted in strengthened progression-free as well as total survival, resulting in FDA commendation as well as a new therapy possibility for patients.